Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... -- Statistics released from a number of organizations show ... the holidays, beginning with Thanksgiving eve, which is now ... The data, highlighted in an Infographic released ... their annual Sober Days for the Holidays public ... and increased rates of DUI injuries and deaths during ...
(Date:11/22/2014)... -- Research and Markets  has announced the addition of ... report to their offering. ... drug market has been expanding rapidly owing to the ... During 2005-2013, sales of recombinant protein drugs available in ... and it is projected that China ...
(Date:11/21/2014)... PARK, Md. , Nov. 21, 2014  The ... today will host the ceremonial groundbreaking of the new ... College Park. The new building will cultivate transformative new ... health.  Taking place at 10:00 a.m. on ... in the Paint Branch Parking Lot, adjacent to the ...
Breaking Medicine Technology:Alarming Stats Show Holiday Drinking an Issue for Many 2China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... 27, 2012 IRIDEX Corporation today announced the ... based on its proprietary MicroPulse™ technology.  The new ... Laser Trabeculoplasty (MLT), was introduced by IRIDEX at ... Surgery (ASCRS). Glaucoma is the ...
... 2012  Hospira, Inc. (NYSE: HSP ), the world,s ... that the company will present at the Bank of America ... 2012, in Las Vegas. The presentation is scheduled ... 16, 2012. It will be available to all interested parties ...
Cached Medicine Technology:IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma 2IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma 3
(Date:11/22/2014)... “Due to my knee replacement surgery, I had to ... using the ice grip attachment, I noticed how dangerous the ... be a safer way to prevent possible injuries, so I ... BLOCK offers added safety and stability in slick and icy ... and damage associated with traditional spiked ice grips. As a ...
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... November 22, 2014 Domestic farmgate ... slightly in 2009-10, due to a fall in ... industry products amid the global financial crisis. ... strength of Australian dairy manufacturers on the international ... products outweighed supply growth, primarily due to supply ...
(Date:11/22/2014)... New York (PRWEB) November 22, 2014 ... on behalf of patients who allegedly developed Type 2 ... in the federal multidistrict litigation now underway in U.S. ... reports. According to court documents, the litigation will convene ... a.m. The Court has directed Lead Counsel for Plaintiffs ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new collection ... the company has also offered an attracting discount on ... supplier of wedding dresses, UWDress.com is good at manufacturing ... guest gowns are provided over 20 colors, which have ... is famous for high quality. Therefore, its sales increased ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Best Wedding Guest dresses Introduced by UWDress.com 2
... , , , , ... health system clients of healthcare information technology (IT) and ... been named 2009 Most Wired award winners, according to the results ... of Hospitals & Health Networks magazine. , , ...
... CareTech Solutions ( www.caretechsolutions.com ), an information technology ... health systems, announced today it has signed a five-year renewal ... (Cincinnati, OH) with IT outsourcing services, continuing a strategic ... the agreement, CareTech will provide The Christ Hospital with a ...
... , , SUNNYVALE, Calif., July 22 ... in the field of radiosurgery, announced today that Radiosurgery Center of ... Island Hospital in Providence, marking the first CyberKnife System in Rhode ... will allow us to provide the most targeted treatment for our ...
... curb hunger, rev up energy , TUESDAY, July 21 ... may curb appetite and boost energy, thereby helping people ... , Prolylcarboxypeptidase (PRCP) regulates the alpha-melanocyte stimulating hormone (alpha-MSH), ... the body,s energy levels. If PRCP enzyme is blocked, ...
... play, nutrition expert says, , WEDNESDAY, July 22 (HealthDay News) ... be the kind of snack that matters, but who eats ... and non-obese women, the healthy-weight women wanted less of the ... "Obese and non-obese women respond to high-energy, high-density snacks in ...
... , , , The National ... and application of the Comparative Effectiveness of health care technologies in ... Summit on Comparative Effectiveness in Cancer Care to be held in ... Pa., July 22 The National Comprehensive Cancer Network ...
Cached Medicine News:Health News:Nine CareTech Solutions Client-Hospitals Named 2009 Most Wired Winners 2Health News:Nine CareTech Solutions Client-Hospitals Named 2009 Most Wired Winners 3Health News:Nine CareTech Solutions Client-Hospitals Named 2009 Most Wired Winners 4Health News:CareTech Extends IT Outsourcing Contract with The Christ Hospital 2Health News:CareTech Extends IT Outsourcing Contract with The Christ Hospital 3Health News:First CyberKnife System in Rhode Island Installed 2Health News:First CyberKnife System in Rhode Island Installed 3Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care 2Health News:NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care 3
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: